RocketTickers
Long

FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic

NASDAQ:SNY   SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II
REGN ,SNY: Sanofi
2019-03-11 15:45:00
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - PR Newswire
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Help Center Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing TradingView Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out